Ruchit Patel


Ruchit Patel


Placeholder image

Ruchit Patel is an antitrust partner in the firm’s London office. Ruchit advises some of the largest companies in the world on matters before the European Commission, UK Competition and Markets Authority, UK sectoral regulators, UK High Court. He also has litigation experience before the UK Competition Appeal Tribunal.

Ruchit also has significant experience advising clients on antitrust law matters in Asia. His clients include technology, financial services, private equity, and healthcare companies, among others.

In 2020, Ruchit was included in GCR’s list of the top young antitrust lawyers in the world: the 40 under 40. Ruchit is also recognized in Chambers UK as an “up and coming” individual in the area of competition law, and Global Competition Review notes he is a “Future Leader.” Clients have commented in Who’s Who Legal that Ruchit is “a very experienced competition lawyer” who “focuses on strategy and results” and “is uniquely dedicated to ensuring his clients’ success” and is “able to coordinate complex projects.” Legal 500 also noted that Ruchit brings “an in-depth knowledge of Indian competition law.” Recognized by Who’s Who Legal’s “Competition 2020—Future Leaders,” Ruchit was named in the “Most Highly Regarded Partners” across Europe designation. 

Ruchit is a visiting Lecturer at the Centre for Commercial Law Studies at Queen Mary University of London.


Strategic Transactions

  • Pfizer Inc. in its acquisition of Trillium Therapeutics Inc. for approximately $2.26 billion
  • Acceleron Pharma on its approximately $11.5 billion million sale to Merck
  • Sunovion Pharmaceuticals, a subsidiary of Japan’s Sumitomo Dainippon Pharma, in a billion-dollar worldwide co-development and co-commercialization agreement with Otsuka Pharmaceutical Co., Ltd. for four novel neurology drugs
  • Takeda Pharmaceutical Company Limited in an exclusive collaboration and license agreement with JCR Pharmaceuticals Co., Ltd. to commercialize JR-141 for the treatment of Hunter syndrome
  • Cove Hill Partners on the sale of LiveAuctioneers to Auction Technology Group plc for approximately $500 million 
  • Baring Private Equity Asia on the sale of the global surgical business of Lumenis LTD. to Boston Scientific
  • Google before the Competition Commission of India in its acquisition of an interest in Reliance Jio Platforms valued at $4.5 billion
  • Wright Medical Group N.V. on its agreement to be acquired by Stryker Corp. in a transaction with a total enterprise value of approximately $5.4 billion
  • Medical Properties Trust on its deal to acquire the real estate of 30 acute care hospital facilities in the United Kingdom for approximately $2 billion
  • Baring Private Equity Asia in its $381 million acquisition of NIIT Technologies Limited (public to private)
  • Milacron Holdings Corp. in the antitrust aspects of its pending $2 billion cash and stock merger with Hillenbrand, Inc.
  • Wieland-Werke AG in its $1.2 billion acquisition of Global Brass and Copper Holdings, Inc.
  • Avista on the antitrust aspects of the sale of Trimb Healthcare to Karo Pharma, cleared subject to divestitures
  • Medtronic on its US$1.64 billion acquisition of Mazor Robotics Ltd
  • Medtronic on the CMA review of its preferred partnership with Animas Corporation
  • Blue Coat on the European aspects of its sale to Symantec valued at over US$4 billion
  • Pfizer on the sale of its Hospira Infusion Business to ICU Medical, valued at US$1 billion
  • Pfizer on its nearly US$14 billion acquisition of Medivation, Inc.
  • Baring Private Equity Asia on its US$1.8 billion sale, alongside the Shanghai-based Bright Food Group, of British breakfast cereal brand Weetabix to U.S.-based cereal company, Post Holdings
  • Medtronic in relation to the European aspects of an acquisition in the medical technology sector valued at over US$1 billion
  • Medtronic on EC and ROW aspects of Medtronic’s US$43 billion acquisition of Covidien. Secured approvals from 13 jurisdictions and coordinated a single remedy globally
  • Biomet, the divestiture buyer, on J&J’s US$21.3 billion acquisition of Synthes
  • Merck on its animal health joint venture with Sanofi-Aventis (ultimately abandoned). Awarded GCR “Deal of the Year” in 2011 in recognition of its size and complexity
  • Abbott on its US$4.5 billion acquisition of Solvay’s pharmaceuticals and diagnostics business, which was conditionally cleared at Phase

Private Equity Transactions

  • Vista Equity Partners in their investment, along with TA Associates Management, in Aptean
  • New Mountain Capital in acquiring ACETO Corporation’s chemicals business assets
  • APG Asset Management on its €450 million joint venture with the US-based Hines Group in Cherrywood, a new home, school and leisure scheme, advising APG in relation to all antitrust aspects of the transaction, including securing clearance from the European Commission
  • Bain Capital on its US$18 billion acquisition of Toshiba Memory Corporation from Toshiba Corporation, by way of a Bain Capital-led consortium including Apple, Seagate Technology, Kingston Technology, Hoya, Dell Technologies and SK Hynix
  • Oakley Capital on the acquisition of TechInsights, a technology patent analysis business


  • Google with several multi-jurisdictional competition law investigations
  • A multinational financial services organisation in the defense of allegations of collusion by the European Commission
  • SK Hynix on settlement negotiations with the European Commission in DRAM
  • IBM with a complaint to the European Commission in relation to “midrange” servers

Litigation & Counseling

  • Metlac in defence of the Competition Commission’s decision to prohibit AkzoNobel’s acquisition of Metlac
  • Boots plc in relation to Celesio’s appeal of the OFT’s decision in Boots/Alliance Unichem in the Competition Appeal Tribunal
  • An intervener in relation to Ofgem’s decision to fine British Gas for exclusionary policy in relation to gas and electricity matter


Ropes & Gray International LLP is a limited liability partnership registered in Delaware, United States of America and is a recognised body regulated by the Solicitors Regulation Authority (with registered number 521000).


  • Deal of Distinction (2021) in the life sciences category by the Licensing Executive Society for a global licensing collaboration to develop small molecule inhibitors for treatment of Parkinson’s disease and movement disorders
  • Chambers UK 2020—Recognized as an “Up and Coming” individual in “Competition Law”
  • Global Competition Review 2020—"40 Under 40" 
  • Global Competition Review 2019—Recognized as a “Future Leader”
  • The Legal 500 US (2018-2019)
  • The Legal 500 UK, EU and Competition (2020)
  • Who’s Who Legal: Competition Future Leaders (2019)



  • Co-author, “United Kingdom,” GLI – Merger Control 2020 (May 2020)
  • Quoted, “Merger changes aren’t necessary, Indian lawyers say,” Global Competition Review (August 17, 2018) 
  • Quoted, “Regulation is ‘greatest risk’ for PE managers,” Private Funds Management (September 29, 2017) 
  • Author, “The Development Of The European Commission’s Decisional Practice On Failing Division Defences,” World Competition, September 2015, (nominated for World Competition’s Legal Writing Award (Under 35 category))
  •  Author, “The Treatment of Late Filings in Indian Merger Control,” World Competition and Indian Lawyer, 2014
  • Co-author, “Dominance,” EC Competition Law Series, Volume V: Abuse of Dominance Under Article 102 TFEU, Claeys & Casteels, September 2013
  • Co-author, “Now the Commission Wants Damages Too… The Commission as Private Damages Claimant and Its Implications,” CPI Antitrust Chronicle, July 15, 2013 (nominated for Concurrences Legal Writing Award for Private Actions)
  • Author, “Barmi v. the Board of Control for Cricket in India: One to Send Upstairs?” Kluwer Competition Law Blog, February 2013
  • Author, “2013: The Wind of Change,” Competition Policy International, January 2013
  • Author, “BIS Reforms to the UK Merger Regime: An Opportunity Missed,” Competition Law Journal, Volume 11/Issue 2, 2012
  • Author, “The Removal of Dishonesty from the Cartel Offence and the Publication Defence: A Panacea?” CPI Antitrust Journal, Spring 2012
  • Author, “The Development of UK Jurisprudence on Hub and Spoke Cartels,” Global Competition Review, October 2010
  • Author, “The English Court of Appeal’s Judgment in Cooper Tire,” Competition Policy International, August 2010
  • Author, “Deliberate Concealment in Cartel Claims,” Competition Policy International, May 2010
  • Guest Editor, Competition Policy International Issue, May 2010
  • Author, “Oral Hearings and the Best Practices Guidelines,” Competition Policy International, March 2010


  • Speaker, “Competition and Digital Platforms,” King’s College London Public Policy Workshop (December 13, 2019) 
  • Moderator, “Navigating the Regulatory Landscape in Private Equity,” Kayo Women's Private Equity 5th Annual Conference (October 3, 2017)
  • Organizer and Participant, Private Equity General Counsel Roundtable (June 27, 2017)
  • Speaker, “Proof Agreements, Incentives and Liabilities in Hub-and-Spoke Antitrust Conspiracies,” The Knowledge Group Webinar (May 16, 2017)
  • Speaker, “Online Platforms and Competition Law: Challenges for Competition Authorities and Policy Matters,” The Center for Innovation, Intellectual Property and Competition (May 4, 2017)
  • Co-host, “Competition in Digital Markets”, U.S.-India Business Counsel Roundtable Discussion (March 29, 2017)
  • Speaker, 3rd International Competition Law Conference (November 12, 2016)
Cookie Settings